Company
ASX:PAB
Based in Melbourne, Australia, Patrys is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications.
68 stories · page 2 of 4
ONJCRI’s Translational Breast Cancer Program and Metastasis Research Laboratory head Professor Robin Anderson will lead the study into incorporating the cell-penetrating antibodies, PAT-DX1 and PAT-DX3, into new metastatic breast cancer tre
The company’s asset PAT-DX1 was shown to significantly improve survival in an animal model of an aggressive and almost universally lethal brain cancer when combined with radiation therapy.
“With the successful conclusion of the PAT-DX1 engineering run, it is now wholly appropriate that Patrys appoints a new chair for its next chapter as it focuses on becoming a clinical stage therapeutic antibody company," Outoing chair John
The company believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.
The company is buoyed by a peer-reviewed publication that reports that Patrys’ deoxymab antibody PAT-DX1 suppresses the formation of neutrophil extracellular traps, which have been implicated in the progression and metastasis of some cancer
“This is one of our most exciting collaborations to date. Professor Johns and his team are leaders in brain cancer translational research in Australia and have numerous international connections," Patrys CEO and managing director Dr James C
“This is an important and exciting appointment for Patrys as we prepare for the first in human studies of PATDX1 in mid-2023, ideally followed by other deoxymab assets,” Patrys CEO and MD Dr James Campbell said.
“With this key reagent now identified and in hand, we can rapidly move into developing a commercial-scale production process to support both the clinical and partnering opportunities we have for PAT-DX3,” says CEO & MD.
In a newsletter on Tuesday, CEO and managing director Dr James Campbell outlined the growing upside in the ADC space — and how Patrys is poised to capitalise on momentum.
The company's wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has also received a $1,188,581 R&D Tax Incentive Refund for the 2020/2021 financial year.
“Having two assets on the path to the clinic is a very exciting place to be, and makes Patrys a much more robust investment opportunity. I personally can’t wait to see what we learn and I encourage you to stay tuned for our updates," says C
“Based on the promising data we have seen for PAT-DX3 since we announced it 12 months ago, we believe there are a range of very attractive potential applications for this deoxymab that will significantly expand opportunities for internal de
“This quarter has delivered a period of significant momentum for Patrys. We have continued to build the portfolio of data for deoxymabs which has further expanded the broad and promising utility for our antibody assets in addition to meetin
“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival," says CEO.
The funds raised through the placement and rights issue will position the company to effectively leverage the wide range of therapeutic opportunities provided by its unique Deoxymab platform.
After four weeks of treatment with PAT-DX1, treated mice showed 93% less brain metastasis than untreated mice.
There is heavy trading activity in the small cap sector today.
Two pre-clinical drug candidates found to effectively target and kill human glioblastoma cancer stem cells in vitro.
The single tranche placement will see new shares issued priced at 3.4 cents.
Shares rise 80% to a 12-month high on strong volume.
